Post-Conference Perspectives: Uveal Melanoma

home / news-network / post-conference-perspectives-uveal-melanoma

Omid Hamid, MD, and Ryan Sullivan, MD, discuss new updates in uveal melanoma, and an exciting, recently approved agent for treatment of metastatic disease.

Omid Hamid, MD, and Ryan Sullivan, MD, smiling at camera

EP. 1: Overview of Metastatic Uveal Melanoma

July 22nd 2022

Ryan Sullivan, MD, provides an overview of metastatic uveal melanoma, currently available treatment options, and unmet needs in the field.

Omid Hamid, MD, and Ryan Sullivan, MD, smiling at camera

EP. 2: Novel Immunotherapy Agent Tebentafusp for Treatment of Metastatic Uveal Melanoma

July 22nd 2022

Dr Omid Hamid explains the mechanism of action of recently approved tebentafusp for mUM, and why HLA testing is necessary for patients being considered for the treatment.

Omid Hamid, MD, and Ryan Sullivan, MD, smiling at the camera. Both are in their offices.

EP. 3: Recent Trial Data on Tebentafusp in Metastatic Uveal Melanoma

July 29th 2022

Dr Ryan Sullivan details clinical trial data presented at ASCO 2022 on the use of tebentafusp for mUM.

Omid Hamid, MD, and Ryan Sullivan, MD, smiling at the camera. Both are in their offices.

EP. 4: Managing Tebentafusp Toxicities in Metastatic Uveal Melanoma

July 29th 2022

Experts highlight strategies for managing the adverse events of tebentafusp, especially cytokine release syndrome.

Omid Hamid, MD, and Ryan Sullivan, MD, smiling at the camera. Both are in their offices.

EP. 5: Future Directions in Metastatic Uveal Melanoma Treatment

August 5th 2022

Omid Hamid, MD, and Ryan Sullivan, MD, discuss what they look forward to in the future of metastatic uveal melanoma treatment.